Seed funding enabled validation of PLP platform chemistry and generated leads in two programs (MYC/WDR5 – oncology; KEAP1/NRF2 – neurodegeneration). Grove’s most advanced program focuses on the MYC interactome. Initial in vivo studies in xenograft mouse models of NSCLC and pancreatic cancer show significant tumor growth inhibition and improved survival at doses of 1mg/kg. Pipeline programs are rapidly advancing, targeting ser/threonine phosphatases, as well as the androgen receptor AR-V7.